Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01846052 · ClinicalTrials.gov registry record
Clinical and Genetic Characterization of Individuals With Achromatopsia
A clinical trial of Achromatopsia, sponsored by Beacon Therapeutics.
- Completed
- Registry status
- 56
- Enrollment target
- 5
- Study locations
NCT01846052 is a study of Achromatopsia that has completed, run by Beacon Therapeutics. The registered enrollment target is 56 participants, below the 6,685-participant average among 3 other Achromatopsia trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT01846052, a study of Achromatopsia, has completed, sponsored by Beacon Therapeutics.
- COMPLETED
- Registry status
- 56 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to identify individuals with achromatopsia caused by mutations in the CNGB3 gene and characterize their clinical condition using several tests of visual function every 6 months for up to 1.5 years.
Conditions Studied
Study Locations (5)
Florida
- VitreoRetinal Associates - Gainesville
- Bascom Palmer Eye Institute - Miami
Illinois
- Pangere Center for Inherited Retinal Diseases, The Chicago Lighthouse for People Who Are Blind or Visually Imp - Chicago
Oregon
- Casey Eye Institute, Oregon Health & Science University - Portland
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2013-06 |
| Est. Completion | 2017-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01846052
The ClinicalTrials.gov registry entry for NCT01846052 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,685-participant average among 3 other Achromatopsia trials with a reported enrollment target (99% lower). The listed sponsor is Beacon Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Achromatopsia appearing as the primary indexed condition, and to 0 interventions.
NCT01846052 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Florida, Illinois, Oregon.
Frequently Asked Questions
What is clinical trial NCT01846052 about?
NCT01846052 is a clinical study titled "Clinical and Genetic Characterization of Individuals With Achromatopsia". The purpose of this study is to identify individuals with achromatopsia caused by mutations in the CNGB3 gene and characterize their clinical condition using several tests of visual function every 6 months for up to 1.5 years.
What is the current status of trial NCT01846052?
This trial is currently completed. The enrollment target is 56 participants. The study started on 2013-06. Estimated completion is 2017-04.
What conditions does trial NCT01846052 study?
This clinical trial studies the following conditions: Achromatopsia.
Who is sponsoring clinical trial NCT01846052?
This trial is sponsored by Beacon Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01846052 being conducted?
This trial has 5 study locations across Florida, Illinois, Oregon, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Achromatopsia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Inherited Retinal Degenerative Disease Registry
RECRUITING
-
Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial)
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.